Clinical Trials Details

Studying Interventions on the Management of Patients with Chronic Myeloid Leukemia (CML)

CA180-330, Chronic Myeloid Leukemia In Chronic Phase: The 5-Year Prospective Cohort Study

Objective

This study is looking at 3 cohorts of patients with Chronic Myeloid Leukemia (CML) treated with imatinib, dasatinib or nilotinib to look at disease management and patient outcomes.  Questionnaire are mailed or emailed to be completed every six months for 5 years.

IRB Protocol Number

CA180330

Principal Investigator(s)

Brock Whittenberger, MD

Sponsor(s)

Simplicity

Contact

Linda Allen, RN OCN at 406-435-7481
or lallen@billingsclinic.org